摘要
目的探讨丹参多酚酸盐联合缬沙坦治疗高血压肾病的临床价值。方法选取医院2015年11月至2017年6月收治的高血压肾病患者93例,采用随机数字表法分为观察组(45例)和对照组(48例)。两组患者均给予常规降压治疗,在此基础上,对照组患者加用缬沙坦胶囊治疗,观察组患者加用丹参多酚酸盐联合缬沙坦胶囊治疗。两组患者均以7 d为1个疗程,共治疗2个疗程。结果观察组总有效率为95.56%,明显高于对照组的77.08%(P<0.05);治疗后,观察组患者肾功能指标[血肌酐(SCr)、尿素氮(BUN)、24 h微量白蛋白(m Alb)]、内皮功能指标[可溶性细胞间黏附分子-1(s ICAM-1)、内皮素-1(ET-1)]、炎性因子[白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)]、氧化应激指标丙二醛(MDA)水平均明显降低(P<0.05),而谷胱甘肽过氧化物酶(GSH-Px)水平明显升高(P<0.05)。结论丹参多酚酸盐联合缬沙坦治疗高血压肾病有助于提高临床疗效,促进肾功能、内皮功能、炎性因子及氧化应激水平的改善。
Objective To investigate the clinical value of salvianolate combined with valsartan in the treatment of hypertensive nephropathy.Methods Totally 93 patients with hypertensive nephropathy admitted to our hospital from November 2015 to June 2017 were selected and divided into the observation group( n = 45) and the control group( n = 48) according to the random number table method. The two groups were given conventional antihypertensive treatment,on this basis,the control group was treated with Valsartan Capsules,while the observation group was treated with salvianolate combined with Valsartan Capsules. The two groups were treated for 2 courses with 7 d for 1 course. Results The total effective rate of the observation group was 95. 56%,which was significantly higher than 77. 08% of the control group( P〈0. 05). After treatment,the indexes of renal function indexes [ serum creatinine( SCr),urea nitrogen( BUN),microalbumin( m Alb) ],endothelial function indexes [ soluble intercellular adhesion molecule-1( s ICAM-1) and endothelin-1( ET-1) ],inflammatory factors [ interleukin 6( IL-6) and tumor necrosis factor α( TNF-α) ],and the levels of oxidative stress index [ malondialdehyde( MDA) ] in the observation group were obviously decreased,while the level of glutathione peroxidase( GSH-Px) in the observation group was obviously increased( P〈0. 05). Conclusion Salvianolate combined with valsartan in the treatment of hypertensive nephropathy can improve the clinical effect,promote the improvement of renal function,endothelial function,inflammatory factors and oxidative stress.
作者
王岚
Wang Lan(Department of Internal Medicine,Afj~liated Hospital of Guizhou Medical University,Guiyang,Guizhou,China 55000)
出处
《中国药业》
CAS
2018年第14期44-46,共3页
China Pharmaceuticals